2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2060

Influence Of Anti-Ro/SSA Autoantibodies On Cinical Characteristic Of a Cohort Of Myositis Patients
Abstract Number: 2305

Influence Of Disease Activity On The Physical Activity Of Rheumatoid Arthritis Patients
Abstract Number: 2856

Influence Of Mechanical Symptoms On Treatment Outcomes For Meniscal Tear In The Setting Of Osteoarthritis
Abstract Number: 811

Influence Of Smoking On Citrullinated Proteins and Porphyromonas Gingivalis In The Lung: A Priming Site For Autoimmunity In RA
Abstract Number: 1515

Influence Of Taking Structural Lesions Into Account In Addition To Inflammatory Lesions On MRI Of The Sacroiliac Joints On The Classification Of Patients With Possible Axial Spondyloarthritis
Abstract Number: 531

Influenza Infection Of MHC-I Transgenic Mice Reveals That Erap Is Necessary and Sufficient For Generation Of The B27-Specific Immunodominant Epitope
Abstract Number: 543

Inhibiting TWEAK (TNF-like weak inducer of apoptosis) Signaling Improves Blood Brain Barrier Integrity and Protects From Neuronal Damage In Murine Neuropsychiatric Lupus
Abstract Number: 2732

Inhibition Of Autophagy Prevents Ovariectomy Induced Bone Loss
Abstract Number: 42

Inhibition Of B Cell Differentiation To The Plasmablast and Plasma Cell Lineage By CC-220, a Potent Modulator Of The Cereblon E3 Ubiquitin Ligase Complex
Abstract Number: 557

Inhibition of Calcium/Calmodulin-Dependent Protein Kinase 4 Ameliorates Th17 Related Autoimmune Disorder
Abstract Number: 822

Inhibition Of Casein Kinase II Reduces TGFβ Induced Fibroblast Activation and Ameliorates Experimental Fibrosis
Abstract Number: 1792

Inhibition Of Chemokine Receptors CCR1 and CCR6 As Promising Therapies For Autoimmune Diseases Such As Rheumatoid Arthritis and Psoriasis
Abstract Number: 2858

Inhibition Of Chronic Pain By IL4-10 Synerkine Is Superior To IL-4 Or IL-10 Monotherapy: A Novel Strategy To Restrain Pain In Rheumatic Diseases
Abstract Number: 2705

Inhibition Of Microrna-155 Ameliorated Experimental Fibrosis By Suppressing Wnt and Akt Pathways
Abstract Number: 2562

Inhibition Of SOX9 Phosphorylation Abrogates The Increased Expression Of Profibrotic Genes In Systemic Sclerosis Dermal Fibroblasts

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].